Evidence map›Paper›PMID 39533028›Full record

ArticleScientific reports2024

ACVR2B polymorphism, Adiponectin, and GDF-15 levels as biomarkers for cachexia in gastrointestinal cancer.

Laura de Martin Coletti, Gabriela Gonzalez Segura, Leticia Cangemi Guedes de Freitas, Jackeline de Souza Rangel Machado, Rene Beleboni, Adilson Faccio, Mozart Marins, Ana Lúcia Fachin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Cancer therapy and cachexia.The Journal of clinical investigation · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Laura de Martin ColettiBiotechnology Unit, University of Ribeirão Preto (UNAERP), Ribeirão Preto, 14096-900, Brazil.
Gabriela Gonzalez SeguraBiotechnology Unit, University of Ribeirão Preto (UNAERP), Ribeirão Preto, 14096-900, Brazil.
Leticia Cangemi Guedes de FreitasBiotechnology Unit, University of Ribeirão Preto (UNAERP), Ribeirão Preto, 14096-900, Brazil.
Jackeline de Souza Rangel MachadoDentillo e Gavio - Identificação E Quantificação Molecular Ltda.-ME, Ribeirão Preto, 14056-680, Brazil.
Rene BeleboniBiotechnology Unit, University of Ribeirão Preto (UNAERP), Ribeirão Preto, 14096-900, Brazil.
Adilson FaccioInstituto Ribeirãopretano de Combate ao Câncer, Ribeirão Preto, 14015-130, Brazil.
Mozart MarinsBiotechnology Unit, University of Ribeirão Preto (UNAERP), Ribeirão Preto, 14096-900, Brazil.
Ana Lúcia FachinBiotechnology Unit, University of Ribeirão Preto (UNAERP), Ribeirão Preto, 14096-900, Brazil. afachin@unaerp.br.

Funding

Fundação de Amparo à Pesquisa do Estado de São Paulo 2023/15218-3
6 · The paper itself

Abstract

Reversing cancer cachexia remains a challenge. Genetic biomarkers for the early detection of the disease have been explored in order to enable the implementation of preventive measures. We therefore genotyped candidate genes based on cachexia phenotype and quantified adiponectin and GDF-15 levels in cachectic patients with gastrointestinal cancer. Patients with a diagnosis of gastrointestinal cancer were divided into a cachectic and a non-cachectic group after the start of chemotherapy. A control group (no cancer) was also included. We genotyped the following single nucleotide polymorphisms (SNPs) by quantitative PCR: FOXO3 (rs1935949), FOXO3 (rs4946935), ACVR2B (rs2268757), and SELP (rs6136). In addition, we quantified adiponectin and GDF-15 levels by ELISA. The rs2268757 SNP in the ACVR2B gene was associated with the weight loss phenotype in cachectic patients with gastrointestinal cancer (non-cachectic, P = 0.004). Plasma adiponectin levels were higher in cachectic patients compared to controls (P = 0.01) and non-cachectic patients (P = 0.004). GDF-15 was also elevated in cachectic patients compared to controls (P < 0.0001) and non-cachectic patients (P = 0.001). Analysis by sex showed elevated adiponectin levels in men (control, P = 0.01) and cachectic women (control, P = 0.04; non-cachectic, P = 0.01), as well as elevated GDF-15 levels in men (control, P = 0.002) and cachectic women (control, P = 0.002; non-cachectic, P = 0.007). However, there was no significant difference in the levels of these cytokines between cachectic men and women. The results suggest the rs2268757 SNP in the ACVR2B gene, adiponectin, and GDF-15 as potential biomarkers of cachexia in gastrointestinal cancer.

Indexed as

Activin Receptors, Type IIAdiponectinCachexiaGastrointestinal NeoplasmsGrowth Differentiation Factor 15Polymorphism, Single NucleotideAgedBiomarkers, TumorCase-Control StudiesFemaleGenotypeHumansMaleMiddle AgedActivin Receptors, Type IIACVR2B protein, humanAdiponectinADIPOQ protein, humanBiomarkers, TumorGDF15 protein, humanGrowth Differentiation Factor 15AdiponectinCachexiaChemotherapyGastrointestinal cancerPolymorphism

Identifiers

PMID39533028
PMCPMC11557708

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.